AIM ImmunoTech (NYSEAMERICAN:AIM) Shares Up 61.3% – Time to Buy?

Shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) shot up 61.3% during mid-day trading on Monday . The company traded as high as $0.6930 and last traded at $0.4080. 470,214,618 shares traded hands during trading, an increase of 49,250% from the average session volume of 952,820 shares. The stock had previously closed at $0.2530.

Analyst Upgrades and Downgrades

Separately, Zacks Research cut shares of AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Buy”.

AIM ImmunoTech Trading Down 38.4%

The stock has a market cap of $2.06 million, a P/E ratio of -0.04 and a beta of 1.24. The firm’s fifty day moving average price is $0.58 and its two-hundred day moving average price is $1.04. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.01 and a quick ratio of 0.53.

AIM ImmunoTech (NYSEAMERICAN:AIM) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.69) earnings per share for the quarter. The firm had revenue of $0.02 million for the quarter. As a group, equities research analysts forecast that AIM ImmunoTech Inc. will post -4.33 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. DRW Securities LLC increased its holdings in shares of AIM ImmunoTech by 60.6% in the fourth quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock worth $79,000 after purchasing an additional 26,254 shares during the period. Sabby Management LLC bought a new position in shares of AIM ImmunoTech in the third quarter worth $79,000. Finally, Corient Private Wealth LLC bought a new position in shares of AIM ImmunoTech in the second quarter worth $87,000. Institutional investors own 12.02% of the company’s stock.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.